Desk›Healthcare› Vineet Laboratories Ltd
Vineet Laboratories Ltd
BSE 543298 · NSE VINEETLAB · ISIN INE505Y01010 · Group B · Active
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
₹38.49
-0.67%
BSE close, 28 August 2026
₹73.92 cr
1.9 cr shares · Micro cap
₹64.71 cr
as published
45.8× · 2.40×
EPS ₹0.84 · BV ₹16.04
59.40 / 1.60
₹ cr, as filed
10
5 selected · 50%
Reg 30
Sch. III Part A
Price 52-week, BSE
| Against 52-week high | -11.6% |
|---|---|
| Against 52-week low | +37.6% |
| Day change | -0.67% |
| Size band | Micro cap |
| Index membership | None |
Valuation as published by BSE
| Earnings per share | ₹0.84 |
|---|---|
| Price / earnings | 45.82× |
| Price / book | 2.40× |
| Book value — derived, price ÷ P/B | ₹16.04 |
| Return on equity | 5.21% |
| Operating margin | 13.37% |
| Net margin | 6.45% |
Consistency check
- P/B ÷ P/E, which must equal ROE
- 5.24%
- ROE as published
- 5.21%
Results ₹ crore, as filed
RevenueNet profit one scale across all three periods, ₹ crore
| Period | Revenue ₹cr | Net profit ₹cr | EPS ₹ | OPM | NPM |
|---|---|---|---|---|---|
| Mar-26 · Q | 18.89 | 1.22 | 0.43 | 13.37% | 6.45% |
| Dec-25 · Q | 15.65 | 0.85 | 0.92 | 16.22% | 5.44% |
| FY25-26 | 59.40 | 1.60 | 1.00 | 14.45% | 2.70% |
Quarter on quarter
- Revenue, quarter on quarter
- +20.7%
- Net profit, quarter on quarter
- +43.5%
- Operating margin, quarter on quarter
- -285 bps
Disclosure profile 10 filings in the window
| Tag | Filings |
|---|---|
| Selected | |
| Auditor Resignation | 1 |
| Board Outcome | 1 |
| Change in Management | 1 |
| Resignation | 1 |
| Results | 1 |
| Selected sub-total | 5 |
| Procedural | |
| Board Meeting | 1 |
| Compliance Certificate | 1 |
| General | 1 |
| Monitoring Agency | 1 |
| Trading Window | 1 |
| Procedural sub-total | 5 |
| Total | 10 |
Disclosure regime
LODR Reg 30
Read with Schedule III Part A. An equity filer in BSE Group B, so the Regulation 30 disclosure framework and the Schedule III event list both apply.
Filing rhythm · 98 trading days
10 filings · 5 selected · busiest 2026-08-25 and 2026-09-30
Filing rhythm · the twelve most recent
2026-07-302026-10-14
SelectedProcedural
Filings
10 in the window · 3 earlier on record
-
14 October 2026 ·
Change in Management
We are hereby submitting the exchange regarding the appointment of Avula Navaneeswara Reddy as Non Executive Non Independent Director of the company with effect from 14th October 2026
Company Update / Change in Management View filing →
-
14 October 2026 ·
Resignation of Director
We wish you to inform you that Mr. Vennapusa Premanand Reddy (DIN:02512956) has ceased to be a director of Vineet Laboratories with effect from October 14, 2026.
Company Update / Resignation of Director View filing →
-
8 October 2026 ·
Clarification Regarding Clerical/Typographical Error In The Cash Flow Statement Of The Audited Financial Results For The Quarter And Year Ended March 31, 2026.
We are hereby clarify that due to clerical oversight, an amount of Rs. 21.29 Lakhs was erroneously reflected under Inc ome taxes paid in the cash flow statement for the year ended 31st march 2026.
Company Update / General View filing →
-
30 September 2026 ·
Resignation of Statutory Auditors
Resignation of Statutory Auditor
Company Update / Resignation of Statutory Auditors View filing →
-
30 September 2026 ·
Closure of Trading Window
The Trading window for dealing in the securities of the Company will remain closed form 01st October, 2026 till 48 hours after the announcement of Standalone Un-audited Financial Results ....
Insider Trading / SAST / Closure of Trading Window View filing →
-
25 August 2026 ·
Results-Delay in Financial Results
The Board of Director of the company in its meeting held on August 25 2026 Approved the Audited Standalone Financial Results for the fourth quarter and the financial year ended on 31st ....
Result / Financial Results View filing →
-
25 August 2026 ·
Board Meeting Outcome for Outcome Of Board Meeting Held On Tuesday, August 25, 2026 As Required Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015
The Board of Directors of the company in its meeting held today i.e., on August 25, 2026 has: Approved the Audited Standalone Financial Results of the Company for the fourth quarter and ....
Board Meeting / Outcome of Board Meeting View filing →
-
20 August 2026 ·
Board Meeting Intimation for Intimation Of The Date Of Board Meeting Under Regulation 29 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Vineet Laboratories Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/08/2026 ,inter alia, to consider and approve the Audited Standalone ....
Board Meeting / Board Meeting View filing →
-
14 August 2026 ·
Monitoring Agency Report
Please find the attached Monitoring Agency Report issued by CRISIL rating Limited for quarter ended June 30, 2026
Company Update / Monitoring Agency Report View filing →
-
30 July 2026 ·
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We are hereby submitting the compliance Certificate issued by Venture Capital and Corporate Inveatments Private Limited
Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 View filing →
RSS feed for Vineet Laboratories Ltd · the 50 most recent filings